Tofacitinib and Disease recurrence - a phase IV clinical study of FDA data

Summary:

Disease recurrence is reported as a side effect among people who take Tofacitinib (tofacitinib), especially for people who are female, 50-59 old, also take Xeljanz, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Disease recurrence when taking Tofacitinib. It is created by eHealthMe based on reports of 5,544 people who have side effects when taking Tofacitinib from the FDA, and is updated regularly.

What is Tofacitinib?

Tofacitinib has active ingredients of tofacitinib. eHealthMe is studying from 5,554 Tofacitinib users. Check the latest studies of Tofacitinib.

What is Disease recurrence?

Disease recurrence is found to be associated with 1,242 drugs and 1,551 conditions by eHealthMe. Check the latest studies of Disease recurrence.

On Jul, 15, 2026

5,544 people reported to have side effects when taking Tofacitinib.
Among them, 85 people (1.53%) have Disease recurrence.

Could Tofacitinib cause Disease recurrence?

Among these 85 people:

What is the gender of people who have Disease recurrence when taking Tofacitinib? *

female: 96 %
male: 4 %

What is the age of people who have Disease recurrence when taking Tofacitinib? *

What are other drugs people take besides Tofacitinib? *

What are other side effects people have besides Disease recurrence? *

Drug Ineffective: 77 people, 90.59%
Therapeutic Response Decreased (less preventive response): 76 people, 89.41%
Drug Intolerance (drug sensitivity): 76 people, 89.41%
Joint Pain: 76 people, 89.41%
Pain: 75 people, 88.24%
Anaphylaxis (serious allergic reaction that is rapid in onset and may cause death): 75 people, 88.24%
Rashes (redness): 75 people, 88.24%
Malaise (a feeling of general discomfort or uneasiness): 75 people, 88.24%
Muscle Spasms (muscle contraction): 75 people, 88.24%
Wrist Deformity: 67 people, 78.82%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 68 people, 80.00%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 60 people, 70.59%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 8 people, 9.41%
Juvenile Rheumatoid Arthritis (joint inflammation in children due to systemic disease): 2 people, 2.35%
Weight Loss: 1 person, 1.18%
Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 1 person, 1.18%
Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 1 person, 1.18%
Ovarian Neoplasm (tumour of ovary): 1 person, 1.18%
Infection: 1 person, 1.18%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 1 person, 1.18%

* Approximation only. Some reports may have incomplete information.

Do you take Tofacitinib and have Disease recurrence?

- Check whether Disease recurrence is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tofacitinib:

Tofacitinib (5,554 reports)

Browse all side effects of Tofacitinib:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Disease recurrence:

Disease recurrence (1,242 drugs)

Browse all the conditions that are associated with Disease recurrence:

Disease recurrence (1,551 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tofacitinib (the active ingredients of Tofacitinib) and Tofacitinib (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.